The combination of mTORC1/2 and PI3Kα inhibition alleviates PI3K pathway reactivation and leads to significant antitumor activity in multiple preclinical xenograft models.

被引：1
|
作者：
Brake, Rachael L. [1 ]
Fabrey, Robyn [2 ]
Szwaya, Jeff [1 ]
Fitzgerald, Michael [1 ]
Iartchouk, Natasha [1 ]
Guo, Xin [2 ]
Kuida, Keisuke [1 ]
Zohren, Fabian [1 ]
Manfredi, Mark [1 ]
机构：
[1] Takeda, Cambridge, MA USA
[2] Takeda Calif, San Diego, CA USA
来源：
MOLECULAR CANCER THERAPEUTICS | 2013年 / 12卷 / 11期
关键词：
D O I：
10.1158/1535-7163.TARG-13-C176
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
C176
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Regulation of mTORC1 by PI3K signaling
    Dibble, Christian C.
    Cantley, Lewis C.
    TRENDS IN CELL BIOLOGY, 2015, 25 (09) : 545 - 555
  • [2] Inhibition of PI3K Alpha and PI3K Delta with Copanlisib Shows Preclinical Activity As a Single Agent and in Combination in Multiple Myeloma
    Larson, Sarah M.
    Peng, Mao Yu
    Mead, Monica
    Vandross, Andrae
    Conklin, Dylan
    Von Euw, Erika
    Slamon, Dennis J.
    BLOOD, 2017, 130
  • [3] PI3K inhibition in preclinical models of HNSCC
    Hedberg, Matthew Louis
    Li, Hua
    Zeng, Yan
    Grandis, Jennifer Rubin
    MOLECULAR CANCER THERAPEUTICS, 2015, 14 (07)
  • [4] The hVps34-SGK3 pathway alleviates sustained PI3K/Akt inhibition by stimulating mTORC1 and tumourgrowth
    Bago, Ruzica
    Sommer, Eeva
    Castel, Pau
    Crafter, Claire
    Bailey, Fiona P.
    Shpiro, Natalia
    Baselga, Jose
    Cross, Darren
    Eyers, Patrick A.
    Alessi, Dario R.
    EMBO JOURNAL, 2016, 35 (17): : 1902 - 1922
  • [5] Comprehensive PI3K pathway inhibition through combination of the PI3Kβ/δ inhibitor AZD8186 and the mTORC1/2 inhibitor AZD2014 drives tumor regression in vivo
    Hancox, Urs
    Polanska, Urszula
    Hanson, Lyndsay
    Ellston, Rebecca
    Maynard, Julia
    Kraus, Manfred
    Curwen, Jon
    Klinowska, Teresa
    Ward, Lara
    Cruzalegui, Francisco
    Green, Stephen
    Symeonides, Stefan
    Cronin, Kathryn
    Barry, Simon
    MOLECULAR CANCER THERAPEUTICS, 2015, 14 (07)
  • [6] In vitro and in vivo antitumor activity of DCBCI0901, a potent PI3K/mTORC1/mTORC2 inhibitor
    Lee, Ying-Shuan E.
    Kuo, Mann-Yan
    Huang, Yi-Ting
    Tseng, Yu-Wen
    Lin, Yu Jie
    Liu, Yen His
    Chiou, Shian-Yi
    Chen, Li Jung
    Lu, Y. -Y.
    Yang, Chih-Hsin
    Yang, Pan-Chyr
    MOLECULAR CANCER THERAPEUTICS, 2013, 12 (11)
  • [7] Mosaic Disorders of the PI3K/PTEN/AKT/TSC/mTORC1 Signaling Pathway
    Nathan, Neera
    Keppler-Noreuil, Kim M.
    Biesecker, Leslie G.
    Moss, Joel
    Darling, Thomas N.
    DERMATOLOGIC CLINICS, 2017, 35 (01) : 51 - +
  • [8] PI3K/mTORC1 activation in hamartoma syndromes Therapeutic prospects
    Krymskaya, Vera P.
    Goncharova, Elena A.
    CELL CYCLE, 2009, 8 (03) : 403 - 413
  • [9] Vertical Inhibition of the mTORC1/mTORC2/PI3K Pathway Shows Synergistic Effects against Melanoma In Vitro and In Vivo
    Werzowa, Johannes
    Koehrer, Stefan
    Strommer, Sabine
    Cejka, Daniel
    Fuereder, Thorsten
    Zebedin, Eva
    Wacheck, Volker
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2011, 131 (02) : 495 - 503
  • [10] mTORC1 inhibition with rapamycin leads to activation of PI3K/AKT signalling via an mTORC2 dependent mechanism in melanoma cells
    Werzowa, J.
    Pratscher, B.
    Cejka, D.
    Pehamberger, H.
    Wacheck, V.
    EJC SUPPLEMENTS, 2006, 4 (12): : 176 - 177
12345